Attached files
file | filename |
---|---|
10-K - 10-K - Altimmune, Inc. | d514795d10k.htm |
EX-32.2 - EX-32.2 - Altimmune, Inc. | d514795dex322.htm |
EX-32.1 - EX-32.1 - Altimmune, Inc. | d514795dex321.htm |
EX-31.2 - EX-31.2 - Altimmune, Inc. | d514795dex312.htm |
EX-31.1 - EX-31.1 - Altimmune, Inc. | d514795dex311.htm |
EX-23.2 - EX-23.2 - Altimmune, Inc. | d514795dex232.htm |
EX-21 - EX-21 - Altimmune, Inc. | d514795dex21.htm |
Exhibit 23.1
Consent of Independent Registered Public Accounting Firm
We consent to the incorporation by reference in the following Registration Statements:
Form | Registration Number | Date Filed | ||
S-3 S-8 S-8 S-3 S-3 S-8 S-3 S-3 |
333-217034 333-217846 333-214765 333-176607 333-161587 333-156371 333-155692 333-146463 |
3/30/2017 5/10/2017 11/22/2016 9/1/2011 8/27/2009 12/19/2008 11/25/2008 10/2/2007 |
of our report dated March 30, 2018, with respect to the consolidated financial statements of Altimmune, Inc,, included in this Annual Report (Form 10-K) of Altimmune, Inc. for the year ended December 31, 2017.
/s/ Ernst & Young LLP
Baltimore, Maryland
March 30, 2018